Prognostic Gene Expression Profiling in Cutaneous Melanoma
Article 2020 en
Authors
DG
Douglas Grossman
NO
Nwanneka Okwundu
EB
Edmund K. Bartlett
Abstract
1 min read
More evidence is needed to support using GEP testing to inform recommendations regarding SLNB, intensity of follow-up or imaging surveillance, and postoperative adjuvant therapy. The MPWG recommends further research to assess the validity and clinical applicability of existing and emerging GEP tests. Decisions on performing GEP testing and patient management based on these results should only be made in the context of discussion of testing limitations with the patient or within a multidisciplinary group.
Tuba N. Gide, Nurudeen A. Adegoke, Michael Xie, Yizhe Mao, Grace H. Attrill, Nigel Maher, Robyn P.M. Saw, Ismael A. Vergara, Matteo S. Carlino, Serigne Lo, Inês Pires da Silva, Jorja Braden, Alexander M. Menzies, Richard A Scolyer, Georgina V. Long, James S. Wilmott
Alexander M. Menzies, Trina Lum, James S. Wilmott, Jessica Hyman, Richard Kefford, John F. Thompson, Sandra A. O’Toole, Georgina V. Long, Richard A Scolyer
Rasmus Mikiver, Roger Olofsson Bagge, Michael A. Marchetti, Alexander Christopher Jonathan Van Akkooi, Daniel G. Coit, Christian Ingvar, Karolin Isaksson, Richard A Scolyer, John F. Thompson, Alexander H. R. Varey, Johan Lyth, Edmund K. Bartlett
Caroline G. Watts, Andrew J. Spillane, Michael A. Henderson, Anne Ε. Cust, Jeffrey Braithwaite, DE Gyorki, AM Hong, Kelly Jw, GV Long, VJ Mar, AM Menzies, Rachael L. Morton, Frances Rapport, Rpm Saw, Helen Schmid, Richard A Scolyer, Al Smith, Abigail Winder, GJ Mann
Discussion(0)
No comments yet. Be the first to comment.